Fairtility VP of Clinical Affairs Dr. Cristina Hickman to Present Additional Findings on CHLOE EQ™’s Ability to Accurately Annotate and Understand Relevance of Embryo Biomarkers to Improve Embryo Selection
TEL AVIV, Israel, Oct. 19, 2022 /PRNewswire/ — Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced today research highlights planned for the American Society of Reproductive Medicine’s 2022 Scientific Congress & Expo taking place in Anaheim, California from October 22-26, 2022. In two oral presentations and six posters, Fairtility will present its newest findings, focusing on the ability of its Embryo Quality Assessment tool, CHLOE EQ™, to unlock both the clinical and operational potential of IVF.
One poster presentation, an exploratory study entitled, “Comprehensive Comparison of Number of Embryology Hours Per Cycle and Risk Before and After Introduction of CHLOE EQ™ (Fairtility) Into a 100% Time-Lapse IVF Clinic,” researchers compared the number of embryologist hours spent per cycle and risks before and after the implementation of the CHLOE EQ™, finding that CHLOE EQ™’s Automatic Time Lapse annotation with direct EMR integration removed 17 of the 24 steps embryologists perform. This resulted in reducing time per cycle from 9.76 to 6.43 hours: a 33 percent reduction in time per cycle spent on mundane administrative tasks, with an associated 50 percent increase in embryology annual cycle capacity.
“Demand for IVF treatment far outstrips supply; there are not enough embryologists to meet the growing demand for IVF treatments, and those embryologists that are in the field are experiencing increased burnout, which leads to more errors, more stress and mental health issues,” said Dr. Cristina Hickman, VP of Clinical Affairs for Fairtility. “The only answer to this challenge is implementing supportive tools like CHLOE, which can relieve workload burdens, increase workflow efficiencies, and increase embryology retention and attraction by lightening the administrative load, not to mention improve our ability to help our patients achieve their hopes of having a child.”
Dr. Hickman will also present the results of a retrospective cohort study conducted in collaboration with Weill Cornell in an oral presentation entitled, “Turning the Black Box Into a Glass Box: Use of Transparent Artificial Intelligence To Understand Biological Markers Useful for Embryo Selection.” The study’s goal was to compare biomarkers automatically annotated by CHLOE EQ™ with human annotations and to better understand their biological relevance. CHLOE was able to accurately annotate in line with rankings by all five embryologists in the study. CHLOE’s accuracy, powered by Fairtility’s transparent AI, allows for consistent embryo assessment and improved information flow between lab, REI, patient and clinic management, leading to reduced operational costs and enhanced standard of care.
“Reproducible results backed by evidence-based research are the cornerstone of reliability and cultivating trust between IVF professionals and the CHLOE EQ™ platform. This is why we continue to invest in research – 40-plus studies providing consistent support for the impact CHLOE’s transparent AI can offer the IVF space,” said Eran Eshed, CEO and Co-founder of Fairtility. “CHLOE can ease the burden and burnout of IVF practitioners, increasing accuracy, impact and transparency in clinical decision making, while also streamlining administration and communication between IVF practitioners, clinic staff and prospective parents. We are just beginning to unlock the operational and clinical efficiency of IVF with CHLOE.”
Fairtility will share two oral presentations at ASRM.
INNER CELL MASS SURFACE AREA AUTOMATICALLY DETECTED USING CHLOE EQ™ (FAIRTILITY), AN AI-BASED EMBRYOLOGY SUPPORT TOOL, IS ASSOCIATED WITH EMBRYO GRADING, EMBRYO RANKING, PLOIDY AND LIVE BIRTH OUTCOME presented by Dr. Cristina Hickman, VP of Clinical Affairs, Fairtility.
TURNING THE BLACK BOX INTO A GLASS BOX: USE OF TRANSPARENT ARTIFICIAL INTELLIGENCE TO UNDERSTAND BIOLOGICAL MARKERS USEFUL FOR EMBRYO SELECTION presented by Dr. Cristina Hickman, VP of Clinical Affairs, Fairtility.
Fairtility’s six ASRM poster sessions include:
P-19 COMPREHENSIVE COMPARISON OF NUMBER OF EMBRYOLOGY HOURS PER CYCLE AND RISK BEFORE AND AFTER INTRODUCTION OF CHLOE EQTM (FAIRTILITY) INTO A 100% TIME-LAPSE IVF CLINIC presented by Dr. Cristina Hickman, VP of Clinical Affairs, Fairtility.
P-11 CAN CHLOE (AN AI-BASED EMBRYOLOGIST ASSISTANT) AUTOMATICALLY PREDICT ON DAY 3 WHETHER AN EMBRYO WILL BECOME A BLASTOCYST , BE UTILISED AND/OR IMPLANT? presented by Jose Teruel MSc, Crespo Valencia, Spain.
P-110 STRONG AGREEMENT BETWEEN MANUAL AND ARTIFICIAL INTELLIGENCE (AI) SUPPORTS AUTOMATED ANNOTATIONS OF TIME-LAPSE CULTURED EMBRYOS AT A SINGLE FERTILITY CLINIC presented by Dr. Cristina Hickman, VP of Clinical Affairs, Fairtility and Adriana Brualla Mora MSc, Fairtility – Spain.
P-12 TRANSPARENT PREDICTION OF BLASTULATION, PLOIDY AND IMPLANTATION: AN INTERNATIONAL MULTISITE VALIDATION AT SIX INDEPENDENT CLINICS presented by Dr. Cristina Hickman, VP of Clinical Affairs, Fairtility.
P-13 WHY SPEND TIME DOING MANUAL ANNOTATIONS WHEN CHLOE EQ™’S AUTOMATIC ANNOTATIONS ARE COMPARABLE TO THAT OF EXPERIENCED EMBRYOLOGISTS? A MULTI-CENTRE COMPARATIVE STUDY presented by Adriana Brualla Mora MSc, Fairtility – Spain.
P-6 CHLOE EQ™ EFFECTIVELY AND AUTOMATICALLY PREDICTS EMBRYO IMPLANTATION ACROSS ALL PATIENT AGE GROUPS BY COMBINING MORPHOKINETIC AND MORPHOLOGY ALGORITHMS OVER CULTURE TIME presented by Assaf Ben-Meir MD, Co-founder of Fairtility and Dr. Cristina Hickman, VP of Clinical Affairs, Fairtility.
About Fairtility
Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes. Equipping clinicians and their patients with unparalleled visibility into IVF treatment, CHLOE™ (Cultivating Human Life through Optimal Embryos) is the first and only transparent AI-based decision support tool that provides clinicians with complete visibility into the clinical and laboratory parameters that make up data output to help improve IVF outcomes. Beginning with CHLOE EQ™, a proprietary embryo grading platform, Fairtility is on a path to expand CHLOE™’s application to span the full IVF journey – from infertility cause assessment through transfer optimization. To learn more about Fairtility™ or schedule a demo, visit our website and follow us on Twitter and LinkedIn.
Media Contact
Nicole Kaufman Grubner
+972-58-444-5418
[email protected]
View original content:https://www.prnewswire.com/news-releases/fairtilitys-embryo-quality-assessment-tool-chloe-eq-could-increase-clinics-ivf-cycle-capacity-by-50-percent-per-embryologist-exploratory-study-highlights-in-asrm-scientific-congress-presentation-301653535.html
SOURCE Fairtility
What happened Shares of Moderna (NASDAQ: MRNA) fell 7.9% on Wednesday after health regulators authorized Novavax's (NASDAQ: NVAX) COVID-19 vaccine, Adjuvanted, as a booster for adults. So what The Centers for Disease Control and Prevention (CDC) will allow Novavax's vaccine to be used as a first booster shot for people aged 18 and older who would rather take it than initial boosters offered by Moderna and Pfizer (NYSE: PFE).
Food and Drug Administration (FDA) authorization for a product typically delivers a nice stock price boost for the affected company. This, however, wasn't the case with vaccine specialist Novavax (NASDAQ: NVAX) on Hump Day, as the latest FDA green light had the opposite effect, driving the shares down by almost 4% on the day. The FDA has granted emergency use authorization (EUA) for Novavax's booster coronavirus shot, an adjuvanted version of its NVX-CoV2373.
The guest model told the magazine that she was unhappy with her body before her breast cancer diagnosis, but that she gained perspective after getting sick.
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.
A nursing home in Homestead recently traded for $18.63 million, according to public records. Signature Healthcare of Brookwood Gardens at 1990 S. Canal Dr. was acquired by 1990 South Canal Dr LLC on Oct.
Alison Appleby — a teen from Sherman, Texas, who has epilepsy and autism — was crowned Miss Dallas Teen 2022 as a pageant newcomer with her seizure alert dog, Brady, by her side.
Cases of “troublesome” COVID-19 variants BQ.1 and BQ.1.1 are quickly rising in the U.S. Here’s what you need to know.
An M.D. candidate explained why you should never use those automatic hand dryers in public bathrooms.
Is it age-related memory loss or dementia? Here’s how to distinguish the two, according to experts.
Soda is synonymous with America. After all, Coca-Cola essentially created the modern depiction of Santa Claus. Ironically, though, vast portions of the country don't even call it "soda."Carbonated, flavored beverages of all kinds are usually referred to as "coke" in the Southern states, while it's common to call soda "pop" in the midwestern regions. Regardless of what it's called, soda has been a major part of American diets for decades.While U.S. soda consumption stats have been declining in re
Eli Lilly & Co. is scooping up a local gene-editing startup at a 121% premium. Lilly (NYSE: LLY) on Tuesday announced that it would acquire Boston-based Akouos Inc. (Nasdaq: AKUS) for $487 million up-front plus one non-tradeable contingent value right per share, which would put the value of the transaction at $610 million. Lilly is valuing each Akouos share at $12.50, a 121% premium over where they had been trading over the previous 30 days on average.
Aveo Oncology shares shot up Tuesday following the company's announcement that it would be acquired by a Korean pharma firm.
This is how to get a good night's sleep when you're stressed – according to the experts.
Strict parenting may increase a child’s predisposition to suffer from depression, new research suggests. A study conducted by researchers from the University of Leuven posited that raising children in an extremely strict manner and environment alters their brain, which could manifest in depression later in life.
The Supplemental Nutrition Assistance Program (SNAP) and the Special Supplemental Nutrition Program for Women, Infants and Children (WIC) are both federally-funded health and nutrition programs. Both…
Flu season is already off to an early start in the United States, and there are reports of pharmacies seeing increased demand for flu antivirals like Tamiflu.
Many health-care companies talk about addressing high costs and health equity, but too many fall flat when in reaping true impact, according to at least one health-care CEO. "We have to clean up our act. None of us is blame-free in this environment of ever-increasing health care costs," SCAN Group & Health Plan CEO Dr. Sachin Jain told Yahoo Finance at the 2022 All Markets Summit. Jain previously served in a number of roles spanning the industry including for federal government, academia, insurance, and Big Pharma.
The two newly identified omicron subvariants, dubbed BQ.1 and BQ.1.1, are spreading fast in the New York region and could account for up to 37% of new cases, according to Centers for Disease Control and Prevention data crunched by NBC News.
The committee acknowledged that the pandemic has gotten better, but believes the world must remain vigilant as the COVID-19 virus has proven unpredictable.
Here’s a comprehensive checklist for your Medicare coverage—take the time to review what you have, and what you’ll need next year